Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
Schedule of Events:
-- Satellite Symposium, Room 111, Thursday, June 14, 2007 8:15-9:45am
"Novel Approaches to Improve Treatment Outcomes in Arthritis"
Co-Chairs: Steven Abramson, MD, Professor, Medicine and Pathology, Hospital for Joint Diseases, New York, NY and Josef Smolen, MD, Professor, Rheumatology, Medical University of Vienna, Vienna, Austria.
-- Poster #THU0051, Thursday, June 14, 2007, 11:45-1:30pm
"Inhibition of Macrophage and Chrondrocyte Inflammatory Mediators by CRx-102, a Novel Synergistic Combination Drug Candidate", Fraser, et.al.
-- Poster #SAT0236, Saturday, June 16, 2007, 10:15-11:45am
"Response and State-Attainment Criteria in Hand OA: Analyses from a Placebo-Controlled Clinical Trial of CRx-102, a Novel Synergistic Combination Therapy", Kvien, et.al.
-- Poster #SAT0049, Saturday, June 16, 2007, 10:15-11:45am
"A Phase 2a Trial to Evaluate CRx-102 for the Treatment of Active Rheumatoid Arthritis", Kirwan, et.al.
Abstracts are currently available online via the EULAR website (www.EULAR.org) and the posters will be available on the CombinatoRx website (www.combinatorx.com) following presentation.
About CRx-102
CRx-102 is an oral synergistic combination drug candidate containing the cardiovascular agent dipyridamole and an unconventionally low dose of the steroid prednisolone. CRx-102 works through a novel mechanism of action in which dipyridamole selectively amplifies prednisolone's anti-inflammatory and immunomodulatory activities without replicating its side effects. In phase 2 clinical trials, CRx-102 demonstrated a powerful anti-inflammatory effect and rapid onset of action in patients with osteoarthritis and rheumatoid arthritis and was generally well tolerated. CRx-102 is being developed in a modified-release commercial formulation for the treatment of multiple immuno-inflammatory diseases.
About CombinatoRx
CombinatoRx, Incorporated (CRXX) is pioneering the new field of synergistic combination pharmaceuticals and has a broad product portfolio in phase 2 clinical development. Going beyond traditional combinations, CombinatoRx creates product candidates with novel mechanisms of action striking at the biological complexities of human disease. The lead programs in the CombinatoRx portfolio are advancing into later stage clinical trials based on the strength of multiple positive phase 2a results. This portfolio is internally generated from the CombinatoRx proprietary drug discovery technology which provides a renewable and previously untapped source of novel drug candidates. The Company was founded in 2000 and is located in Cambridge, Massachusetts. To learn more about CombinatoRx please visit www.combinatorx.com.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning CombinatoRx, its strategic development, its product candidates and their clinical potential, its plans for clinical and formulation development of its product candidates, its business plans and its drug discovery technology. These forward-looking statements about future expectations, plans and prospects of CombinatoRx involve significant risks, uncertainties and assumptions, including risks related to the unproven nature of the CombinatoRx drug discovery technology, the Company's ability to initiate and successfully complete clinical trials of its product candidates, the Company's ability to develop a modified release formulation of CRx-102, potential difficulty and delays in obtaining regulatory approval for the sale and marketing of its product candidates, the Company's ability to obtain additional financing or funding for its research and development and those other risks that can be found in the "Risk Factors" section of the CombinatoRx Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that CombinatoRx periodically files with the Securities and Exchange Commission. Actual results may differ materially from those CombinatoRx contemplated by these forward-looking statements. CombinatoRx does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.
(c) 2007 CombinatoRx, Incorporated. All rights reserved.
Contact
CombinatoRx, Incorporated
Robert Forrester, 617-301-7100
Executive Vice President, Chief Financial Officer
Fax: 617-301-7010
rforrester@combinatorx.com
or
Gina Nugent, 617-301-7099
VP, Corporate Communications and IR
Fax: 617-301-7010
gnugent@combinatorx.com
Posted: June 2007
